Bavituximab With Radiation and Temozolomide for Patients With Newly Diagnosed Glioblastoma
Status:
Active, not recruiting
Trial end date:
2022-08-31
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of drugs with radiation as a possible treatment
for Glioblastoma.
The drugs involved in this study are:
- Bavituximab
- Temozolomide
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
National Comprehensive Cancer Network Peregrine Pharmaceuticals